Young-Onset Colon Cancer and Recurrence Risk By Gene Expression

George J Chang 1, Y Nancy Y You 1, Christy A Russell 2, Marni B Tierno 2, Michelle Turner 2, John P Bennett 2, Anna Lau 2, Howard S Hochster 3

Affiliations

PMID: 32040172
DOI: 10.1093/jnci/djaa019

Abstract

The incidence and mortality from colorectal cancer in younger adults (<55 years) is increasing. We reviewed the complete database of a gene-expression test, Oncotype DX Colon Recurrence Score® test, to determine age-related differences in Recurrence Score® (RS) and single-gene results (7 cancer-related of the 12-gene assay). We included 20,478 Stage II & III A/B colon cancer patients submitted to Genomic Health. RS results were grouped by low, intermediate, and high risk groups. Single-gene scores were described using median and interquartile range. Seventy-two and a half percent of all patients and 72.6% of those <40 years had low risk RS. Comparing older versus younger patients, RS or single-gene expression did not differ by age group or stage. Young-onset colon cancer does not differ by expression of the RS component genes. Most patients with stage II/III colon cancer have low-risk disease as measured by the 12-gene assay, regardless of age.

Similar articles

Translating Tumor Biology Into Personalized Treatment Planning: Analytical Performance Characteristics of the Oncotype DX Colon Cancer Assay
KM Clark-Langone et al. BMC Cancer 10, 691. 2010. PMID 21176237.
Analytical performance characteristics shown here for both individual genes and gene groups in the Oncotype DX Colon Cancer Assay demonstrate consistent translation of sp …
Association Between Partial-Volume Corrected SUVmax and Oncotype DX Recurrence Score in Early-Stage, ER-positive/HER2-negative Invasive Breast Cancer
SH Lee et al. Eur J Nucl Med Mol Imaging 43 (9), 1574-84. Aug 2016. PMID 27209424.
High PVC-SUVmax on (18)F-FDG PET/CT was significantly associated with an intermediate-to-high Oncotype DX RS. PVC metabolic parameters on (18)F-FDG PET/CT can be used to …
A Comparison of 12-gene Colon Cancer Assay Gene Expression in African American and Caucasian Patients With Stage II Colon Cancer
R Govindarajan et al. BMC Cancer 16, 368. 2016. PMID 27316467.
The distribution of Recurrence Score results and gene expression data was similar in a cohort of AA and CA patients with stage II colon cancer and similar clinical charac …
Oncotype DX(®) Colon Cancer Assay for Prediction of Recurrence Risk in Patients With Stage II and III Colon Cancer: A Review of the Evidence
YN You et al. Surg Oncol 24 (2), 61-6. Jun 2015. PMID 25770397. - Review
Advances in molecular biology have enabled identification of tumor biomarkers that allow for individualized risk assessment for patients with cancer. Molecular predictors …
Evolving Role of Gene Expression Signatures as Biomarkers in Early-Stage Colon Cancer
G Goel. J Gastrointest Cancer 45 (4), 399-404. Dec 2014. PMID 24989938. - Review
In such an evolving landscape, this article aims to review the current role of gene expression signatures such as Oncotype DX and ColoPrint in the management of early-sta …